Sep 2026· Journal of the American Chemical Society· 0 citations· 37 references
TL;DR
The limit of quantification is improved to the fmol level in native biological environments, enabling the direct identification of neoantigens from as few as 5000 cells within 30 min, and the identification of a native Epstein–Barr virus-associated neoantigen is demonstrated.
Abstract
Tumor-specific neoantigens have been the most promising targets for TCR-based cancer therapies; however, their detection is greatly hindered by low abundance, sequence variability, and potential modifications. To address these, we developed a digital nanopore framework to unambiguously identify and effectively quantify candidate neoantigens directly in cell samples via event-resolved molecular identification and counting. By engineering a multirecognition-region nanopore and developing a universal water-osmosis driving force, we simultaneously enhanced the detection throughput and specificity. Combined with enriched current signatures and a gradient-boosting decision-tree classifier, the platform identifies individual ovalbumin-derived model neoantigens with single-amino-acid resolution from digitally assigned events in both exogenously incubated and endogenously expressed cell samples. We show that the limit of quantification is improved to the fmol level in native biological environments, enabling the direct identification of neoantigens from as few as 5000 cells within 30 min. We further demonstrate the identification of a native Epstein–Barr virus-associated neoantigen, highlighting the potential of this approach in ultrasensitive analysis of rare biomolecular species directly in biological samples.
Accessible molecular diagnostics is fundamental to effective healthcare. While most current point-of-care devices detect only the presence of a molecular biomarker(s), biomarker quantification can be equally important for decision-making on disease treatment and containment. Here, we present a diagnostic platform that...
A single microbead-confined dual-mode detection system that selectively captures TEXs for concurrent quantification of protein and miRNA biomarkers and is the first demonstration of a universal PNA modification strategy that harnesses a DNA mediator to prevent AuNPs self-aggregation.
Zhi-Heng Luo, Peng-Bo Zhang, Mou Li et al.· Biosensors & bioelectronics· 0 citations
Traditional adventitious virus testing of biological drugs has missed the presence of viral contaminants in the past. Next-generation sequencing (NGS) has emerged as a promising additional tool with unprecedented capability for breadth of detection. This study introduces a Nanopore-based NGS workflow for detection of...
M. Karbiener, Tim Walker, S. Rudd et al.· Scientific Reports· 0 citations
A protein corona-based secretome profiling strategy is developed and incorporated into a multiomics analytical framework, enabling secretome profiling in a model that better preserves tumor heterogeneity and microenvironmental context and establishes a robust and scalable strategy for incorporating the secretome into m...
Cai-Wei Hu, Jia-Liang Zhao, Qian Li et al.· Analytical Chemistry· 0 citations
The MIRACLE platform is developed, an integrated system combining microfluidic magneto-controllable reversible affinity capture with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for efficient, multiplexed detection of tumor-derived EV DNA mutations.
Effective T cell–based immunotherapies require functional receptors that can be engineered and redeployed to recognize tumor-restricted antigens. Noncanonical peptides arising from transcription outside annotated protein-coding regions expand the antigenic landscape of cancer; however, systematic strategies to biologic...
T. Hulen, M. D. Crowther, Luke Alexander Schuster et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.